Prime

Type your tag names separated by a space and hit enter

[Cannabinoid applications in glaucoma].

Abstract

INTRODUCTION

Glaucoma is a slowly progressive optic neuropathy that is one of the leading causes of legal blindness throughout the world. Currently there is a limited group of topical drugs for the medical treatment of glaucoma is currently limited, and research needs to be focused on new therapeutic horizons, such as the potential usefulness of the cannabinoid agonists for the treatment of glaucoma.

AIM

To review the current scientific literature related to the beneficial effects derived from the different ways of administration of cannabinoids indicated for the glaucomatous optic neuropathy.

DEVELOPMENT

Cannabinoid receptors have shown an intense expression in ocular tissues implicated in the regulation of the intraocular pressure, as well as inner layers of the retina. Through activation of CB1 and CB1 specific receptors and through other still unknown pathways, the cannabinoid agonists have shown both a clear hypotensive, as well as an experimentally proved neuroprotective effect on retinal ganglion cells.

CONCLUSIONS

Some cannabinoid agonists (WIN 55212-2, anandamide) have demonstrated, in experimental studies, to act as «ideal drugs» in the management of glaucoma, as they have been shown to have good tolerability after topical application, efficiently reduce intraocular pressure, and behave as neuroprotectors on retinal ganglion cells. Further studies as regards the safety and clinical assays must be carried out in order to examine the effectiveness of these drugs for the treatment of glaucoma in our daily clinical practice.

Links

  • Publisher Full Text
  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Departamento de Biología Celular e Histología, Grupo de Oftalmo-Biología Experimental (GOBE), Facultad de Medicina, Universidad del País Vasco (UPV/EHU), Leioa, Vizcaya, España.

    ,

    Source

    MeSH

    Animals
    Arachidonic Acids
    Benzoxazines
    Cannabinoid Receptor Agonists
    Cannabinoid Receptor Modulators
    Cannabinoids
    Drug Administration Routes
    Drug Evaluation, Preclinical
    Endocannabinoids
    Excitatory Amino Acid Antagonists
    Eye Proteins
    Glaucoma
    Glutamic Acid
    Humans
    Intraocular Pressure
    Mammals
    Morpholines
    Naphthalenes
    Neuroprotective Agents
    Optic Nerve
    Polyunsaturated Alkamides
    Receptors, Cannabinoid
    Retinal Ganglion Cells
    Vasodilator Agents

    Pub Type(s)

    English Abstract
    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    spa

    PubMed ID

    21414525